RCT | Orlistat and a low-carb diet show promising results for the treatment of Metabolic-Associated Fatty Liver Disease

Summary: The study aimed to compare the effects of orlistat or a high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and metabolic-associated fatty liver disease (MAFLD) over 24 weeks. The primary endpoint was the relative change in liver fat content (LFC) assessed by MRI-PDFF. A total of 118 patients were randomly assigned to the control group, orlistat group, or experimental diet group. All three groups demonstrated improvement in liver steatosis at week 24, with the orlistat group and the experimental diet group both showing a significant decrease in LFC compared to the control group.*

Article: Treatment of Obesity and Metabolic-Associated Fatty Liver Disease with a Diet or Orlistat: A Randomized Controlled Trial – American Journal of Clinical Nutrition

Commentary: The efficiency of lifestyle intervention, orlistat, and experimental diet therapy in patients with obesity and metabolic-associated fatty liver disease – News Medical

*Note: This summary was created through the collaboration of a medical editor and ChatGPT.